<DOC>
	<DOC>NCT02127788</DOC>
	<brief_summary>The purpose of this observational study is to describe the actual conditions of prescription of micafungin in antifungal prophylaxis in French haematological and onco-haematological units. The efficacy and the safety outcomes will be described.</brief_summary>
	<brief_title>Use of Micafungin (MycamineÂ®) as Antifungal Prophylaxis in Haematology and Onco-haematology</brief_title>
	<detailed_description />
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Antifungal Agents</mesh_term>
	<mesh_term>Miconazole</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor. Patient hospitalized in haematology, oncohaematology or oncopaediatrics unit. Patient initiating antifungal prophylaxis with micafungin. Patient presenting documented fungal infection. Patient already included in a biomedical study impacting the care management of invasive fungal infection at the time of inclusion.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Haematology</keyword>
	<keyword>Micafungin</keyword>
	<keyword>Observational study</keyword>
	<keyword>Prophylaxis</keyword>
	<keyword>Invasive Fungal Infection</keyword>
	<keyword>France</keyword>
</DOC>